Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Hepatic Encephalopathy Clinical Trials

A listing of Hepatic Encephalopathy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (4) clinical trials

Fecal Microbiota Transplant as Treatment of Hepatic Encephalopathy

Decades of investigation demonstrate that hepatic encephalopathy (HE), a common complication of cirrhosis characterized by impaired cognition, develops as a consequence of intestinal microbial products reaching the brain. Recent investigation has found that cirrhotic patients, especially those who have developed HE, have intestinal dysbiosis compared to normal controls. Several plausible ...

Phase

The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy

Hepatic encephalopathy is a frequent and occasionally refractory complication of cirrhosis and is associated with impaired quality of life. Its severity may not correlate with other parameters of liver dysfunction. Although multiple pathogenic mechanisms for the condition have been proposed, most include the participation of bacterial toxins, especially ammonia, produced ...

Phase

Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)

The primary objective of this study is to assess the efficacy of rifaximin SSD plus lactulose versus placebo plus lactulose for the treatment of overt hepatic encephalopathy (OHE). The secondary objectives of this study are to assess the safety of rifaximin SSD in subjects with OHE and to assess the ...

Phase

HEAL STUDY (HEPATIC ENCEPHALOPATHY and ALBUMIN STUDY): A DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL OF ALBUMIN IN HEPATIC ENCEPHALOPATHY

Hepatic encephalopathy (HE) is a highly prevalent neuro-cognitive complication of cirrhosis characterized by cognitive dysfunction, and high rate of subsequent mortality and recurrence1. HE also places a tremendous burden with a relentless increase in inpatient stay duration with charges topping $7244.7 million in 20092, 3. There were almost 23,000 hospitalizations ...

Phase